May 18, 2023 – Cleveland Clinic has successfully implanted a dual cardiac device in the first patient in the world as part of a clinical trial, which aims to potentially treat heart failure symptoms.
The INTEGRA-D clinical study will evaluate the safety and effectiveness of a device that combines two proven cardiac therapies into one. Cardiac contractility modulation works to improve the contraction of the heart, while an implantable cardioverter defibrillator (ICD) treats life-threatening arrhythmias that cause sudden cardiac death.
According to the Centers for Disease Control and Prevention, heart failure affects an estimated 6.2 million Americans. These patients experience debilitating symptoms, including breathlessness, fatigue, confusion and swelling in the legs that can greatly diminish quality of life. Most heart failure patients are prescribed medications that work to slow the disease’s progression and manage symptoms, but effectiveness can wane over time. While standard, existing implantable cardiovascular defibrillators are lifesaving, the technology alone does not improve the debilitating symptoms of heart failure.
The clinical trial, sponsored by Impulse Dynamics, manufacturer of the device, will enroll 300 patients from 75 centers across the U.S. who will be followed for two years.